What is the share price of Syngene International Ltd (SYNGENE) today?
The share price of SYNGENE as on 7th May 2026 is ₹473.05. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Syngene International Ltd (SYNGENE) share?
The past returns of Syngene International Ltd (SYNGENE) share are- Past 1 week: 1.64%
- Past 1 month: 15.09%
- Past 3 months: 0.55%
- Past 6 months: -27.47%
- Past 1 year: -27.26%
- Past 3 years: -35.29%
- Past 5 years: -23.46%
What are the peers or stocks similar to Syngene International Ltd (SYNGENE)?
The peers or stocks similar to Syngene International Ltd (SYNGENE) include:What is the dividend yield % of Syngene International Ltd (SYNGENE) share?
The current dividend yield of Syngene International Ltd (SYNGENE) is 0.28.What is the market cap of Syngene International Ltd (SYNGENE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Syngene International Ltd (SYNGENE) is ₹18115.69 Cr as of 7th May 2026.What is the 52 week high and low of Syngene International Ltd (SYNGENE) share?
The 52-week high of Syngene International Ltd (SYNGENE) is ₹728.60 and the 52-week low is ₹380.What is the PE and PB ratio of Syngene International Ltd (SYNGENE) stock?
The P/E (price-to-earnings) ratio of Syngene International Ltd (SYNGENE) is 57.20. The P/B (price-to-book) ratio is 3.83.Which sector does Syngene International Ltd (SYNGENE) belong to?
Syngene International Ltd (SYNGENE) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.How to buy Syngene International Ltd (SYNGENE) shares?
You can directly buy Syngene International Ltd (SYNGENE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Syngene International Ltd
SYNGENE Share Price
NSE₹473.055.10% (+22.95)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SYNGENE Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SYNGENE Performance & Key Metrics
SYNGENE Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 57.20 | 3.83 | 0.28% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 41.10 | 6.15 | 0.54% |
63%
Analysts have suggested that investors can buy this stock
from 8 analysts
Price Upside
Earnings Growth
Rev. Growth
SYNGENE Company Profile
Syngene International Limited is a contract research company. It is engaged in providing contract research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies.
DIVISLAB
PE Ratio
81.20
81.20
1Y Return
8.78%
8.78%
Buy Reco %
65.22
65.22
AARTIPHARM
PE Ratio
26.24
26.24
1Y Return
12.86%
12.86%
Buy Reco %
0.00
0.00
PE Ratio
914.76
914.76
1Y Return
3.06%
3.06%
Buy Reco %
0.00
0.00
VIMTALABS
PE Ratio
29.43
29.43
1Y Return
4.18%
4.18%
Buy Reco %
0.00
0.00
PE Ratio
64.63
64.63
1Y Return
20.56%
20.56%
Buy Reco %
0.00
0.00
SYNGENE Sentiment Analysis
SYNGENE Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SYNGENE Stock Summary · May 2026
Syngene is strategically transitioning towards a technology-led model, emphasizing AI and digital innovations to enhance operational efficiency and drive future growth, particularly in the CDMO sector. Despite a modest 3% revenue growth in FY26, with a notable 13% sequential increase in Q4, the company faces challenges from ongoing destocking issues and rising labor costs, which have impacted EBITDA margins. However, strong cash generation and a healthy pipeline of advanced modalities, including antibody drug conjugates, position Syngene for recovery and expansion. The extension of key partnerships, such as with Bristol-Myers Squibb, underscores a commitment to long-term client engagement, while cost management initiatives aim to sustain profitability amidst external pressures. Overall, the sentiment remains cautiously optimistic as the company navigates these dynamics, with expectations for improved performance in FY27.
SYNGENE Stock Growth Drivers
SYNGENE Stock Growth Drivers
9Strong Financial Performance in Q4 FY26
In the fourth quarter of FY26, the company reported revenue from operations of INR 1,037
Healthy Cash Flow and Financial Discipline
The company generated a healthy INR 521 crores in free cash during the year, ending
SYNGENE Stock Challenges
SYNGENE Stock Challenges
6Declining Profitability
The company has reported a significant decline in profitability, with profit after tax (excluding exceptional
Impact of Librela on Growth
The ongoing issues related to Librela have negatively impacted the company's growth and profitability. Excluding
SYNGENE Forecast
SYNGENE Forecasts
Price
Revenue
Earnings
SYNGENE Share Price Forecast
SYNGENE Share Price Forecast
2026
Current
₹450.10
Baseline
Forecast for May 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹450.10
Baseline
Forecast for May 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
SYNGENE Company Revenue Forecast
SYNGENE Company Revenue Forecast
2026
Current
₹3.81
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹3.81
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
SYNGENE Stock EPS (Earnings Per Share) Forecast
SYNGENE Stock EPS (Earnings Per Share) Forecast
2026
Current
₹7.87
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹7.87
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
SYNGENE
SYNGENE
Income
Balance Sheet
Cash Flow
Quarterly Normal View
SYNGENE Income Statement
SYNGENE Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 882.80 | 933.00 | 839.80 | 907.50 | 962.00 | 1,036.90 | 892.20 | 926.00 | 932.50 | 1,058.70 | ||||||||||
Operating & Other expenses | 625.70 | 600.00 | 619.90 | 646.20 | 660.10 | 674.40 | 668.10 | 711.10 | 778.50 | 739.10 | ||||||||||
EBITDA | 257.10 | 333.00 | 219.90 | 261.30 | 301.90 | 362.50 | 224.10 | 214.90 | 154.00 | 319.60 | ||||||||||
| Depreciation/Amortization | 108.10 | 111.10 | 106.90 | 110.90 | 108.70 | 106.10 | 111.20 | 116.50 | 113.70 | 111.50 | ||||||||||
| PBIT | 149.00 | 221.90 | 113.00 | 150.40 | 193.20 | 256.40 | 112.90 | 98.40 | 40.30 | 208.10 | ||||||||||
| Interest & Other Items | 10.80 | 12.90 | 11.70 | 13.10 | 12.40 | 15.90 | 11.60 | 13.20 | 11.90 | 12.10 | ||||||||||
| PBT | 138.20 | 209.00 | 101.30 | 137.30 | 180.80 | 240.50 | 101.30 | 85.20 | 28.40 | 196.00 | ||||||||||
| Taxes & Other Items | 26.70 | 20.40 | 25.60 | 31.20 | 49.70 | 57.20 | 14.60 | 18.10 | 13.40 | 48.10 | ||||||||||
| Net Income | 111.50 | 188.60 | 75.70 | 106.10 | 131.10 | 183.30 | 86.70 | 67.10 | 15.00 | 147.90 | ||||||||||
| EPS | 2.78 | 4.70 | 1.89 | 2.64 | 3.27 | 4.56 | 2.16 | 1.67 | 0.37 | 3.68 |
SYNGENE Company Updates
FY 2026FY 2026
Investor Presentation
Apr 30PDF
Jan 23PDF
Dec 17PDF
+3 more
SYNGENE Stock Peers
SYNGENE Past Performance & Peer Comparison
SYNGENE Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareLabs & Life Sciences Services
Compare valuation on Screener
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Syngene International Ltd | 57.20 | 3.83 | 0.28% |
| Divi's Laboratories Ltd | 81.20 | 11.89 | 0.45% |
| Aarti Pharmalabs Ltd | 26.24 | 3.59 | 0.63% |
| Dishman Carbogen Amcis Ltd | 914.76 | 0.51 | — |
SYNGENE Stock Price Comparison
Compare SYNGENE with any stock or ETFCompare SYNGENE with any stock or ETF
SYNGENE
SYNGENE Holdings
SYNGENE Shareholdings
SYNGENE Promoter Holdings Trend
SYNGENE Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SYNGENE Institutional Holdings Trend
SYNGENE Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has decreased by 1.06%
SYNGENE Shareholding Pattern
SYNGENE Shareholding Pattern
SYNGENE Shareholding History
SYNGENE Shareholding History
Foreign Institutions
Mutual Funds Invested in SYNGENE
Mutual Funds Invested in SYNGENE
No mutual funds holding trends are available
Top 5 Mutual Funds holding Syngene International Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.7116% | Percentage of the fund’s portfolio invested in the stock 0.50% | Change in the portfolio weight of the stock over the last 3 months 0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 205/263 (-5) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2367% | Percentage of the fund’s portfolio invested in the stock 2.98% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 17/35 (-4) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2219% | Percentage of the fund’s portfolio invested in the stock 3.52% | Change in the portfolio weight of the stock over the last 3 months 0.54% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 9/44 (+1) |
Compare 3-month MF holding change on Screener
smallcases containing SYNGENE stock
smallcases containing SYNGENE stock
Looks like this stock is not in any smallcase yet.
SYNGENE Events
SYNGENE Events
SYNGENE Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SYNGENE has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.28%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.78 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SYNGENE Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SYNGENE has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.28%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.78 every year
SYNGENE Upcoming Dividends
SYNGENE Upcoming Dividends
Cash Dividend
Ex DateEx DateJun 25, 2026
Final
Final | Div/Share: ₹1.25
Dividend/Share
₹1.25
Ex DateEx Date
Jun 25, 2026
SYNGENE Past Dividends
SYNGENE Past Dividends
Cash Dividend
Ex DateEx DateJun 27, 2025
Final
Final | Div/Share: ₹1.25
Dividend/Share
₹1.25
Ex DateEx Date
Jun 27, 2025
Cash Dividend
Ex DateEx DateJun 28, 2024
Final
Final | Div/Share: ₹1.25
Dividend/Share
₹1.25
Ex DateEx Date
Jun 28, 2024
Cash Dividend
Ex DateEx DateJun 30, 2023
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Jun 30, 2023
Cash Dividend
Ex DateEx DateJun 30, 2023
Special
Special | Div/Share: ₹0.75
Dividend/Share
₹0.75
Ex DateEx Date
Jun 30, 2023
Cash Dividend
Ex DateEx DateJun 30, 2022
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Jun 30, 2022
SYNGENE Stock News & Opinions
SYNGENE Stock News & Opinions
Articles & Videos
Spotlight
Volumes spurt at Syngene International Ltd counter
Cemindia Projects Ltd, Meesho Ltd, Newgen Software Technologies Ltd, Navin Fluorine International Ltd are among the other stocks to see a surge in volumes on NSE today, 30 April 2026.Syngene International Ltd notched up volume of 484.8 lakh shares by 14:14 IST on NSE, a 69.03 fold spurt over two-week average daily volume of 7.02 lakh shares. The stock rose 13.14% to Rs.488.95. Volumes stood at 6.31 lakh shares in the last session.Cemindia Projects Ltd notched up volume of 197.2 lakh shares by 14:14 IST on NSE, a 61.91 fold spurt over two-week average daily volume of 3.19 lakh shares. The stock rose 20.00% to Rs.815.25. Volumes stood at 5.3 lakh shares in the last session.Meesho Ltd saw volume of 1183.74 lakh shares by 14:14 IST on NSE, a 14.24 fold spurt over two-week average daily volume of 83.13 lakh shares. The stock increased 12.20% to Rs.193.75. Volumes stood at 43.37 lakh shares in the last session.Newgen Software Technologies Ltd witnessed volume of 105.24 lakh shares by 14:14 IST on NSE, a 9.22 times surge over two-week average daily volume of 11.42 lakh shares. The stock increased 6.71% to Rs.512.35. Volumes stood at 6.86 lakh shares in the last session.Navin Fluorine International Ltd clocked volume of 20.53 lakh shares by 14:14 IST on NSE, a 8.19 times surge over two-week average daily volume of 2.51 lakh shares. The stock gained 0.69% to Rs.6,805.00. Volumes stood at 3.15 lakh shares in the last session.Powered by Capital Market - Live
6 days agoCapital Market - Live
Corporate
Board of Syngene International recommends final dividend
Syngene International announced that the Board of Directors of the Company at its meeting held on 29 April 2026, inter alia, have recommended the final dividend of Rs 1.25 per equity Share (i.e. 12.5%) , subject to the approval of the shareholders.
1 week agoCapital Market - Live
Corporate
Syngene International schedules AGM
Syngene International announced that the 33th Annual General Meeting(AGM) of the company will be held on 29 July 2026.
1 week agoCapital Market - Live
Earnings
Syngene International consolidated net profit declines 19.31% in the March 2026 quarter
Net profit of Syngene International declined 19.31% to Rs 147.90 crore in the quarter ended March 2026 as against Rs 183.30 crore during the previous quarter ended March 2025. Sales rose 1.82% to Rs 1036.50 crore in the quarter ended March 2026 as against Rs 1018.00 crore during the previous quarter ended March 2025. For the full year,net profit declined 36.17% to Rs 316.70 crore in the year ended March 2026 as against Rs 496.20 crore during the previous year ended March 2025. Sales rose 2.64% to Rs 3738.70 crore in the year ended March 2026 as against Rs 3642.40 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1036.501018.00 2 3738.703642.40 3 OPM %29.2733.75 -24.5728.60 - PBDT313.50346.60 -10 940.401060.50 -11 PBT202.00240.50 -16 487.50627.90 -22 NP147.90183.30 -19 316.70496.20 -36 Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Syngene International to hold board meeting
Syngene International will hold a meeting of the Board of Directors of the Company on 29 April 2026.
3 weeks agoCapital Market - Live
Spotlight
Syngene Intl tumbles after MD & CEO Peter Bains resigns; Siddharth Mittal to take charge
Following his exit, the board has approved the appointment of Siddharth Mittal as an additional director, designated as MD & CEO with effect from 1 July 2026. Mittal previously served as MD and CEO of Biocon. He joined the company in May 2013 and served as president & chief financial officer until November 2019. He brings over two decades of experience in strategic finance, M&A, and general management. During his tenure, he contributed to the growth of the biosimilars business and its transition into Biocon Biologics in 2019. Under Siddharth's leadership, Biocon moved decisively into complex peptides and GLP-1 therapies, stepping into one of the most strategically significant segments in modern pharma. He also led the company's entry into the Generic Formulations segment, building a portfolio of over 20 products across global markets. Meanwhile, the board has also approved the redesignation of Kiran Mazumdar-Shaw from non-executive chairperson to executive chairperson, subject to shareholders' approval. Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The company's consolidated net profit declined 88.56% to Rs 15 crore on 2.82% fall in revenue from operations to Rs 917.1 crore in Q3 FY26 over Q3 FY25.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Syngene International consolidated net profit declines 88.56% in the December 2025 quarter
Net profit of Syngene International declined 88.56% to Rs 15.00 crore in the quarter ended December 2025 as against Rs 131.10 crore during the previous quarter ended December 2024. Sales declined 2.82% to Rs 917.10 crore in the quarter ended December 2025 as against Rs 943.70 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales917.10943.70 -3 OPM %22.8130.05 - PBDT212.70289.50 -27 PBT99.00180.80 -45 NP15.00131.10 -89 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Syngene International to conduct board meeting
Syngene International will hold a meeting of the Board of Directors of the Company on 22 January 2026.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Syngene International consolidated net profit declines 36.76% in the September 2025 quarter
Net profit of Syngene International declined 36.76% to Rs 67.10 crore in the quarter ended September 2025 as against Rs 106.10 crore during the previous quarter ended September 2024. Sales rose 2.20% to Rs 910.60 crore in the quarter ended September 2025 as against Rs 891.00 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales910.60891.00 2 OPM %21.9127.47 - PBDT201.70248.20 -19 PBT85.20137.30 -38 NP67.10106.10 -37 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Syngene International schedules board meeting
Syngene International will hold a meeting of the Board of Directors of the Company on 5 November 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 11.59%, vs industry avg of 10.53%
Over the last 5 years, market share decreased from 21.43% to 19.68%
Over the last 5 years, net income has grown at a yearly rate of 3.78%, vs industry avg of 7.25%